Evidence that the aversive effects of opioid antagonists and κ-agonists are centrally mediated

The role of central versus peripheral opioid receptors in mediating the aversive effects of opioids was examined by use of an unbiased place preference conditioning procedure in rats. The non-selective opioid antagonist naloxone (NLX) produced conditioned aversions for the drug-associated place after subcutaneous (SC) as well as intracerebroventricular (ICV) administration. Place aversions were also observed in response to the ICV administration of the selective -antagonist CTOP. In contrast, the selective -antagonist ICI 174,864 and the selective -antagonist norbinaltorphimine (nor-BNI) (ICV) were without effect. Place aversions were also produced by central applications of the selective -agonist U50,488H and the dynorphin derivative E-2078. For those opioid ligands tested, the doses required to produce place aversions were substantially lower following ICV as compared to SC administration. These data confirm that -agonists and opioid antagonists produce aversive states in the drug-naive animal and demonstrate that this effect is centrally mediated. Furthermore, the ability of NLX and CTOP, in contrast to both ICI 174,864 and nor-BNI, to produce place aversions suggests that the aversive effects of opioid antagonists result from the blockade of -receptors.     

Rewarding properties of β-endorphin as measured by conditioned place preference

The role of -endorphin as a possible mediator in the reinforcing properties of opiates was investigated using a conditioned place preference paradigm. Heroin, a synthetic opiate known to have reinforcing properties, produced a strong preference for an environment previously paired with heroin injection at all doses tested (0.25, 0.5, 1.0, 2.0 mg/kg SC). No such place preference was observed following saline injections. Rats also showed dose-dependent place preference for the environment paired with -endorphin when injected intracerebroventricularly (significant dose was 2.5 g). At higher doses (5.0 and 10.0 g) rats showed no preference for the paired environment, but were catatonic. Pretreatment with naloxone (0.04, 0.2, 1.0 mg/kg SC) attenuated the rewarding effect of -endorphin (2.5 g) at all doses tested. The lowest dose of naloxone which had no aversive effect when tested alone could also significantly block the positive effect of -endorphin. The reinforcing dose of -endorphin (2.5 g) also produced an increase in locomotor activity, when tested in photocell cages. This suggests that the hyperactivity induced by -endorphin may contribute to the preference for an environment previously paired with the same drug. The reinforcing effect of -endorphin is most probably mediated by the mu and/or delta opioid subtype receptor, since -endorphin has a high affinity for these receptors. These results demonstrate positive reinforcing properties of -endorphin in the central nervous system.     

Infusion of γ2-MSH produce a conditioned taste aversion in morphine-dependent rats

A two flavour, unbiased, taste preference conditioning procedure was used to test for possible motivating effects of ₂-MSH. Three training trials failed to produce any significant effect with doses ranging from 2.4 to 40 g/ ICV infusion in drug-naive, non-operated or placebo-implanted rats. However, in rats made dependent by SC implantation of a morphine pellet 4 days earlier 15 g ₂-MSH/infusion produced a taste aversion that was comparable to that produced by infusion of a low dose of the competitive opioid receptor antagonist naloxone (0.32 g). The findings confirm with a conditioning procedure and with opiate-dependent animals the naloxone-like effects of ₂-MSH. They also suggest that this endogenously-located peptide may acquire an aversive property as a result of chronic morphine treatment.     

Aversive properties of naloxone in non-dependent (naive) rats may involve blockade of central β-endorphin

The present study examines the influence of destruction of the medio-basal arcuate hypothalamus (MBH), the primary site of synthesis of central pools of -endorphin (-EP), upon the aversive properties of naloxone in a conditioned place preference paradigm. Bilateral radiofrequency lesions of the MBH resulted in a pronounced fall in levels of immunoreactive -EP in the brain. Lesioned rats, in contrast to non-operated animals, showed a clear reduction in the conditioned place aversion produced by naloxone. However, they showed no loss of the conditioned preference produced by the mu-selective opioid receptor agonist, morphine, or the conditioned aversion produced by the kappaselective agonist, U50-488. In contrast to the effect of the lesions, suppression of circulating -EP by dexamethasone treatment failed to influence conditioning produced by naloxone. Thus, the data indicate that the aversive properties of naloxone are attenuated by disruption of central (but not peripheral) -EP activity. We suggest that these properties of naloxone reflect an antagonism of -EP activity in the brain. In addition, the data indicate that differing mechanisms underlie the aversive actions of naloxone as compared to U50-488.     

Investigation of the involvement of opioid receptors in the action of anticonvulsants

This study investigates the possible involvement of opioid receptors in the action of a variety of anticonvulsant agents. The opioid antagonist naloxone (0.3, 1 mg/kg IP) and the selective -opioid antagonist cyprodime (3 mg/kg IP) significantly inhibited the increase in electroshock seizure threshold induced by phenytoin (3 mg/kg IP) in mice. The anticonvulsant effects of ethanol (1 g/kg IP) were also significantly antagonised by naloxone (1 mg/kg IP) but not by a 0.3 mg/kg IP dose or by cyprodime (3 mg/kg IP). The results with naloxone were confirmed using higher doses of phenytoin (10 mg/kg IP) and ethanol (1.5 g/kg IP). In contrast to the above findings, naloxone (0.3, 1 mg/kg IP) had no effect on the increase in seizure threshold induced by sodium valproate (200 mg/kg IP) or dizocilpine (MK801, 0.5 mg/kg IP) and paradoxically potentiated the increase in seizure threshold produced by phenobarbitone (15 mg/kg IP); carbamazepine (10 mg/kg IP) and the benzodiazepine agonist loprazolam (1 mg/kg IP), clearly differentiating these compounds from phenytoin and ethanol. These findings suggest that the anticonvulsant effects of phenytoin and ethanol (as assessed by their ability to prevent tonic hindlimb extension in the mouse electroshock model) may be mediated, at least in part, by the release of endogenous opioids and subsequent activation of opioid receptors (, in the case of phenytoin, but non-, in the case of ethanol) although direct activity at opioid receptors cannot be precluded.     

Effects of heroin,alone or in combination with other drugs,on the locomotor activity in two inbred strains of mice

The locomotor activity of C57B1/6J and DBA/2J mice was studied, under the influences of heroin, amphetamine, strychnine, or ethanol, and of combinations of the opiate with each one of the other drugs. Heroin treatment was followed by the typical running fit in the C57 mice, while the DBA strain was unaffected. Amphetamine enhanced the activity in the C57 strain only. The combination of heroin with amphetamine or ethanol increased the locomotor activity only in the DBA strain, while heroin + strychnine exerted a clear stimulating effect on the activity of the C57 mice. The strychnine + heroin mixture was more toxic than heroin alone when the lethal doses (LD50) were determined in the 2 strains.     

Inhibition of dopamine-sensitive adenylate cyclase by opioids: possible involvement of physically associated µ- and δ-opioid receptors

Summary D-1 dopamine receptor-stimulated cyclic AMP efflux from rat neostriatal slices (induced by 30 M dopamine + 10 M (–)sulpiride) was concentration-dependently reduced by morphine, [abetd-Ala-abetd-Leu]-enkaphalin (DADLE), [d-Pen-abetd-Pen]enkephalin (DPDPE) and bremazocine. Naloxone (0.1 M) selectively antagonized the inhibitory effect of (a submaximally effective concentration of) morphine, whereas ICI 174864 (0.75 M) completely blocked the inhibitory effects of DADLE, DPDPE and bremazocine without affecting that of morphine, indicating a role of µ- as well as -opioid receptors. Upon simultaneous activation of D-1 dopamine receptors and b-opioid receptors the (-receptor-mediated) inhibitory effect of morphine was abolished, while it was not changed following simultaneous activation of D-1 and (inhibitory) D-2 dopamine receptors. Cyclic AMP efflux induced by isoprenaline or adenosine was not affected by the opioids and that induced by vasoactive intestinal peptide (VIP) was inhibited by morphine and DADLE only. In the latter case naloxone, but not ICI 174864, antagonized the inhibitory effects.These data show that D-1 dopamine receptor-stimulated adenylate cyclase activity in rat neostriatum, but not that stimulated through other receptors, is inhibited by two pharmacologically distinct opioid receptor subtypes. It is speculated that these - and -opioid receptors share a common inhibitory guanine nucleotide binding protein and may represent closely associated recognition sites of a functional opioid receptor complex. Send offprint requests to A. N. M. Schoffelmeer at the above address     

Intrathecal substance P depresses spinal motor and sensory responses to stimulation of nociceptive afferents — Antagonism by naloxone

Summary The effect of an injection of substance P into the subarachnoid space was studied on a motor and a sensory response elicited by supramaximal stimulation of the sural nerve in spinal rats. Substance P 10 g depressed the reflex activation in the electromyogram recorded from the ipsilateral tibialis anterior muscle; the depression was significant 5 and 10 min after the injection. Substance P 10 g reduced the activity in ascending axons of the spinal cord evoked by stimulation of afferent C fibres; the effect developed slowly, lasted longer than 60 min and was abolished by an i.v. injection of naloxone 0.2 mg/kg. Only half the number of ascending axons tested showed a depression by substance P, and the administration of a higher dose (50 g) did not produce an effect in a greater number of axons. Substance P did not influence the activity evoked in ascending axons by stimulation of afferent A and A fibres. The depression by substance P of ascending nociceptive activity was antagonized by an i.v. injection of naloxone 0.2 mg/kg. When naloxone 0.2 mg/ng i.v. was administered alone, it increased the activity in ascending axons activated by afferent C fibre stimulation. It is concluded that (i) substance P depresses spinal nociceptive activity without the intermediation of endorphinergic neurons, and (ii) naloxone antagonizes tonic inhibition of the spinal nociceptive system mediated by endogenous opioid peptides and, by facilitating excitatory transmission through disinhibition, neutralizes the depression produced by substance P.Supported by the Sonderforschungsbereich 38 Membranforschung     

Inhibition by interleukin-1\ of noradrenaline release in rat spleen: involvement of lymphocytes,NO and opioid receptors

Effects of indomethacin, N-nitro-L-arginine (NNA) and naloxone, and of pretreatment with cyclophosphamide (CY), on the interleukin (IL)-I\ induced inhibition of exocytotic noradrenaline release were investigated in the isolated, vascularly perfused spleen of the rat. Neurotransmitter release was evoked by perivascular electrical stimulation (4 Hz) and the overflow of endogenous noradrenaline was determined by HPLC with electrochemical detection.Perfusion of the spleen with Tyrode's solution containing IL-1\ (100 pg/ml) for 90 min caused an inhibition of the stimulation-evoked noradrenaline overflow which persisted for at least 20 min after washout of the IL. The evoked overflow was reduced in the presence of NNA 30 mol/l, but remained unaffected by indomethacin 3 mol/l, naloxone 0.1 mol/l or treatment of the rats with CY (250 mg/kg). The opioid agonist etorphine 10 mol/1 inhibited the evoked overflow of noradrenaline and this effect was prevented by naloxone 0.1 mol/1. The inhibition of evoked overflow by IL-1\ was not affected by indomethacin but was reduced or even prevented in the presence of NNA or naloxone, or after lymphocyte depletion of spleens by CY.The results are compatible with the idea that in the rat spleen exocytotic noradrenaline release is accompanied by a concomitant secretion of a nitric oxide (NO)-like compound which, in turn, reinforces noradrenaline release, and that the release can be inhibited via prejunctional opioid receptors. The IL-1\ induced inhibition of evoked release appears to be a complex process which involves as one of many steps a decrease of the facilitatory NO-like compound and the release of endogenous opioids probably from spleen lymphocytes.     

Anti-nociceptive effect of morphine,opioid analgesics and haloperidol injected into the caudate nucleus of the rat

Summary The effect of intracaudate (i.c.) microinjections of morphine, opioid analgesics and haloperidol was determined on the tail-flick response evoked by radiant heat in rats. Bilateral injections (0.2 l on each side) into the caudate nuclei of morphine 5 g, pethidine 50 g, levorphanol 4 g, dextrorphan 10 g and haloperidol 5 g significantly increased the reaction time of the tail-flick response. The antinociceptive effect of an i.c. injection of morphine or levorphanol was abolished by an intraperitoneal (i.p.) injection of naloxone 0.2 mg/kg or apomorphine 2 mg/kg. The anti-nociceptive effect of pethidine, dextrorphan and haloperidol was reduced but not abolished by an i.p. injection of naloxone 0.2 mg/kg. An i.p. injection of apomorphine 2 mg/kg abolished the effect of an i.c. injection of haloperidol. A bilateral i.c. injection of naloxone 5 g or apomorphine 10 g reduced the anti-nociceptive effect of an i.p. injection of morphine 2 mg/kg or haloperidol 2 mg/kg, but did not abolish it. It is concluded that (1) an anti-nociceptive effect can be achieved by an action on the caudate nucleus of the drugs tested; (2) the anti-nociceptive effect exerted by morphine and levorphanol in the caudate nucleus is due to a specific action mediated by opiate receptors, whilst that produced by pethidine and dextrorphan is due to a specific and/or unspecific action; (3) the anti-nociceptive effect of haloperidol in the caudate nucleus is due to an impairment of dopaminergic impulse transmission, which is also involved in the effect of morphine and levorphanol.Supported by the Sonderforschungsbereich 38 Membranforschung     

Intrathecal substance P depresses the tail-flick response — Antagonism by naloxone

Summary Substance P injected into the lumbar subarachnoid space of rats depressed the tail-flick response to radiant heat in a dose-dependent way. The effective doses ranged from 0.1 g to 100 g per rat (ED 50: 1.5 g/rat). The maximum of the effect was reached 20 min after intrathecal injection and the effect lasted for about 30 min. An antinociceptive effect was also observed after intrathecal injection of substance P 1 g to spinal rats. The depression of the tail-flick response produced by intrathecal administration of substance P was abolished by intrathecal (5 g/rat) or i.p. (0.5 mg/kg) injections of naloxone.Supported by the Sonderforschungsbereich 38 Membranforschung     

The role of brain norepinephrine in clonidine suppression of isolation-induced distress in the domestic chick

Distress vocalizations (DV) induced by social isolation were measured in 1-day-old domestic chicks after intracerebroventricular injections of drugs believed to exert their effects through the noradrenergic system. The -adreno-receptor agonist clonidine reliably suppressed DV rates at doses low as 0.08 g. When given alone, phentolamine, phenoxybenzamine, propranolol, sotalol, and yohimbine (adrenoreceptor antagonists) did not reliably after DV rates at doses that were not toxic. The clonidine DV suppression was reliably reversed by yohimbine (1.75 g), but by none of the other adrenoceptor antagonists or naloxone. 6-Hydroxydopamine at doses as high as 120 g, which essentially eliminated forebrain norepinephrine, failed to suppress DV rates reliably when given alone and, when given in combination with clonidine (0.1 g) or morphine (0.05 g), failed to reverse the severe DV suppression imposed by these drugs. The results suggest that clonidine suppresses DV rates in chicks through interaction with postsynaptic adrenoreceptors or by some means other than prejunctional ₂-adrenoreceptor stimulation.     

Effects of diltiazem,a Ca2+ channel blocker,on naloxone-precipitated changes in dopamine and its metabolites in the brains of opioid-dependent rats

The effects of diltiazem, an L-type Ca²⁺ channel blocker, on naloxone (an opioid receptor antagonist)-precipitated withdrawal signs and changes in extracellular levels of dopamine (DA) and its metabolites in various brain regions of morphine (a -opioid receptor agonist) or butorphanol (a// mixed opioid receptor agonist) dependent rats were investigated using high performance liquid chromatography fitted with an electrochemical detector (HPLC-ED). Rats were rendered opioid-dependent by continuous intracerebroventricular (ICV) infusion with morphine (26 nmol/µl per h) or butorphanol (26 nmol/µ1 per h) for 3 days. The expression of physical dependence produced by these opioids, as evaluated by naloxone (5 mg/kg, IP)-precipitated withdrawal signs, was reduced by concomitant infusion of diltiazem (10 and 100 nmol/µl per h). Under the same condition, naloxone decreased the levels of: DA in the cortex, striatum, and midbrain; 3,4-dihydroxyphenylacetic acid (DOPAC) in the cortex, striatum, limbic areas, and midbrain; and homovanilic acid (HVA) in the striatum, limbic areas, and midbrain regions. In animals rendered dependent on butorphanol, the results obtained were similar to those of morphine-dependent rats except for the changes in DOPAC levels. Furthermore, concomitant infusion of diltiazem and opioids blocked the decreases in levels of DA, DOPAC, and HVA in a dosedependent manner. These results suggest that the augmentation of intracellular Ca²⁺ mediated through L-type Ca²⁺ channels during continuous opioid infusion results in a decrease in extracellular levels of DA and its metabolites in some specific regions, which are intimately involved in the expression of withdrawal syndrome precipitated by naloxone.     

Involvement of opioid receptors in N-Methyl-d-aspartate-induced arterial hypertension in periaqueductal gray matter

Arterial hypertension induced by microinjections of N-methyl-d-aspartate (NMDA) (2 nmol/rat) into the midbrain periaqueductal gray matter was used to assess the involvement of opioid receptors (µ, and ) in modulating pressor periaqueductal gray neurons. Groups (n = 5 – 8) of urethane-anaesthetised rats received, 5 min before NMDA, microinjections of selective opioid receptor antagonists in the periaqueductal gray area and arterial blood pressure was monitored. Pretreatments with naloxone (5 nmol/rat), a non selective ,µ receptor antagonist, or naltrindole hydrochloride (5 nmol/rat), a selective receptor antagonist, significantly (P< 0.05) decreased by 31% and 37%, respectively, NMDA-induced hypertension. The latency for the maximum increase of NMDA-induced hypertension was also significantly (P<0.05) increased with naloxone. Pretreatment with nor-binaltorphimine (5 nmol/rat), a selective receptor antagonist, only increased the latency of NMDA-induced hypertension. Each opioid antagonist failed per se to alter arterial blood pressure. Microinjection of morphine (13 nmol/rat), a non selective ,µ receptor agonist, significantly decreased (P<0.05) by 57.5% NMDA-induced arterial hypertension and this effect was antagonised by naloxone. Combined pretreatments in the periaqueductal gray area with naloxone and the GABA_A antagonist bicuculline (2.5 nmol/rat; 5 min before naloxone) antagonised the effect of naloxone on NMDA induced hypertension. In contrast, bicuculline significantly (P<0.05) potentiated morphine-induced decrease of NMDA hypertension. Combined pretreatments in the periaqueductal gray area with naloxone and the glycine antagonist strychnine (8 nmol/rat; 5 min before naloxone) failed to prevent the effect of naloxone on the NMDA-induced cardiovascular changes.These data suggest that periaqueductal gray vasopressor neurons receive both direct opioid and GABAergic inhibitory inputs. The latter may be, in turn, negatively modulated by opioid fibres mainly through µ and subtype receptors.     

Effects of microinjections of μ and κ receptor agonists into the dorsal periaqueductal gray of rats submitted to the plus maze test

Several lines of evidence have shown that aversive states are under the influence of opioid mechanisms in the dorsal periaqueductal gray (DPAG). In order to characterize the type of opioid receptors involved in these effects in this work we injected DAMGO and U50,488H, and selective agonists, respectively, directly in this structure. Rats implanted with chemitrode in the DPAG were submitted to the elevated plus maze test for 5 min. The effects of DAMGO (0.1–1 nmol/0.2l) and U50,488H (1–10 nmol/0.2 µl) following administration into DPAG were studied. Low doses of DAMGO (0.1 and 0.3 nmol) caused dose-dependent increases in the number of entries and time spent in the open arms while an overall deficit in the exploratory activity was produced by the higher dose used (1.0 nmol). Clear aversive effects were observed following the administration of U50,488H in the DPAG. The antiaversive effects of 0.3 nmol DAMGO were inhibited by the intraperitoneal administration of the receptor antagonist naltrexone (2.0 mg/kg, IP) whereas the aversive effects of 5.0 nmol U50,488H were antagonized by the selective receptor antagonist nor-binaltorphimine (1.0 mg/kg, IP). It is suggested that activation of receptors inhibit and receptors enhance the neural substrate of aversion in the DPAG.     

β-endorphin-sensitive opioid receptors in the rat tail artery

Summary Isolated tail arteries of rats were perfused and field-stimulated every 2 min with 2 pulses at 1 Hz. Different opioid peptides depressed the contractile responses to stimulation; their concentration-response curves showed a maximum at about 40% inhibition. The rank order of potency of the peptides was -endorphin (IC₅₀ = 97 nmol/1) BAM-22P > FK-33824 > DAGO > [d-Ala²,d-Leu⁵]-enkephalin metorphamide > dynorphin A-(1-13) [Met⁵]enkephalin. All these substances have in common a certain activity at opioid -receptors, although the enkephalins are preferential -, and the dynorphins preferential -agonists. However, the selective -agonist [d-Pen²,l-Pen⁵]enkephalin was ineffective at up to 10 mol/l, and the -agonists ethylketocyclazocine and U-50488 acted only at concentrations higher than 3 mol/l. Whereas the effects of -endorphin, DAGO and [d-Ala²,d-Leu⁵]enkephalin could be reduced by the -preferential antagonist naloxone, the effects of ethylketocyclazocine and U-50488 were not changed. The -selective antagonist ICI 174864 did not influence the action of [d-Ala²,d-Leu⁵]enkephalin. Naloxone in a concentration (1 mol/l) which nearly abolished the effect of DAGO 3 mol/l, slightly enhanced responses to stimulation. Neither -endorphin nor DAGO influenced vasoconstriction evoked by the application of noradrenaline or adenosine triphosphate; U-50488 reduced it. In arteries preincubated with [³H]noradrenaline DAGO depressed, whereas naloxone enhanced the tritium overflow and vasoconstriction evoked by field stimulation (0.4 Hz, 24 pulses every 14 min). In addition, naloxone antagonized the effect of DAGO. We suggest that the axon terminals of postganglionic sympathetic neurones in the rat tail artery possess -endorphin-sensitive opioid receptors of the -type. The activation of these receptors by exogenous or endogenous opioids inhibits the release of the neuroeffector transmitter.This work was supported by the Deutsche Forschungsgemeinschaft (SFB 325) Send offprint requests to P. Illes at the above address     

Nicotine and smoking: Effects upon subjective changes in mood

A Mood Adjective Check List and an activation scale were used to measure subjective reports on mood changes in 24 male habitual smokers before and after smoking cigarettes with known content of nicotine, at different times of day and rates of puffing. Ratings on pleasantness were dose related. Aggression and anxiety showed effects attributable to circadian influence and slight decreases in both factors occurred after smoking the highest nicotine cigarette. The MACL scores were greatly affected by the experimental procedure. Levels of inner tension were found related to the nicotine inhaled. The heuristic value of the concept of activation in these studies is suggested.This work was supported by the Tobacco Research Council, and carried out at the Institute of Psychiatry, London.     

Anti-cholinergic effect of verapamil on the muscarinic acetylcholine receptor-gated K+ channel in isolated guinea-pig atrial myocytes

Summary Effects of verapamil on the acetylcholine (ACh)-induced K⁺ current were examined in single atrial cells, using the tight-seal whole-cell clamp technique. The pipette solution contained guanosine-5-triphosphate (GTP) or guanosine-5-O-(3-thiotriphosphate) (GTP-S, a non-hydrolysable GTP analogue). In GTP-loaded cells, ACh induced a specific K⁺ current, which is known to be mediated by pertussis toxin-sensitive GTP-binding (G) proteins. Verapamil (0.1–100 M) depressed the ACh-induced K⁺ current in a concentration-dependent fashion. In GTP-S-loaded cells, the K⁺ current remained persistently after wash-out of ACh, probably due to irreversible activation of G proteins by GTP-S. Verapamil (0.1–100 M) also depressed the intracellular GTP-S-induced K⁺ current. However, the magnitude of verapamil-depression of the K⁺ current in GTP-S-loaded cells was significantly smaller than that in GTP-loaded cells at concentrations between 1 and 10 M of the drug. From these results, it is suggested that verapamil may block not only the function of muscarinic ACh receptors but also of G proteins and/or the K⁺ channel itself and thereby depress the ACh-induced K⁺ current in isolated atrial myocytes.Supported by grants from the Ministry of Education, Science and Culture of Japan and the Research Program on Ca Signal Control Send offprint requests to Y. Kurachi at the above address     

Effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and gastric mucosal cyclic AMP

Summary The effect of the phosphodiesterase inhibitor 4-(3-cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711) on gastric secretion and the cyclic AMP system of the gastric mucosa was studied in rats and guinea pigs. In rats, 0.03–0.3 moles/kg ZK 62711 i.v. stimulated acid and pepsin secretion in a dose-dependent manner and 0.03 moles/kg i.v. enhanced the effect of histamine. In guinea pigs no reproducible stimulation was found after intravenous injections of ZK 62711. The stimulation of gastric secretion in the rat by 0.3 moles/kg ZK 62711 i.v. was not affected by vagotomy but was totally inhibited by 10 moles/kg cimetidine i.v. The structurally related phosphodiesterase inhibitor, 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidine (Ro 20-1724), at the dose of 3.3 moles/kg i.v. stimulated gastric secretion in anaesthetised rats to a similar extent as 0.3 moles/kg ZK 62711 i.v. The content of cyclic AMP in the rat gastric mucosa in vivo was slightly increased by 10 moles/kg ZK 62711 i.v, whereas lower doses did not change it. Accumulation of cyclic AMP in the rat gastric mucosa by 50 moles/kg histamine i.v. was enhanced by simultaneous injections of 3.3 moles/kg ZK 62711 i.v. In rat gastric tissue slices in vitro 1–50 M ZK 62711 increased the level of cyclic AMP but 100 M histamine had no effect in the absence or presence of ZK 62711. In gastric mucosal slices of the guinea pig 10 and 50 M ZK 62711 increased the cyclic AMP content which effect was inhibited by 100 M cimetidine and enhanced the stimulatory effect of 100 M histamine on cyclic AMP. The activity of soluble cyclic AMP phosphodiesterase was inhibited by ZK 62711 in the rat (IC₅₀=18 M) and guinea pig gastric mucosa (IC₅₀=1.5 M). Adenylate cyclase was not affected in the homogenate of the guinea pig gastric mucosa. The results indicate that the phosphodiesterase inhibitor ZK 62711 which increases cyclic AMP levels in the gastric mucosa in vivo and in vitro, is a potent stimulator of gastric acid secretion.